Osimertinib

Osimertinib
Name	Osimertinib
Tradename	Tagrisso
Routes of administration	Oral
Class	Tyrosine kinase inhibitor
Atc prefix	L01
Atc suffix	EX09
Legal status	Prescription only
Metabolism	CYP3A
Elimination half-life	~48 hours
Excretion	Feces, urine

Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for treatment of certain non-small cell lung cancer populations. It targets tumors with specific EGFR mutations and is used in advanced disease and adjuvant settings, following evidence from randomized trials and regulatory decisions. The drug's development, pivotal studies, and safety profile intersect with major oncology organizations, pharmaceutical manufacturers, and regulatory agencies.

Medical uses

Osimertinib is indicated for adult patients with advanced non-small cell lung cancer harboring EGFR sensitizing mutations, including those with acquired EGFR T790M resistance, informed by testing standards from organizations such as American Society of Clinical Oncology, College of American Pathologists, European Society for Medical Oncology, National Comprehensive Cancer Network, and regulatory guidance from the Food and Drug Administration and European Medicines Agency. Clinical practice incorporates companion diagnostics and molecular profiling workflows offered by companies like Roche, Thermo Fisher Scientific, and Qiagen, and is aligned with pathology services at institutions such as Mayo Clinic, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center. In the adjuvant setting, indications reflect outcomes from trials that led to approval decisions involving policymakers in regions served by agencies such as Medicines and Healthcare products Regulatory Agency and health technology assessment by bodies like National Institute for Health and Care Excellence.

Pharmacology

Osimertinib is a selective, irreversible inhibitor that preferentially binds mutant forms of the EGFR kinase domain identified in metastatic non-small cell lung cancer specimens analyzed using sequencing platforms like those developed by Illumina and Ion Torrent. Pharmacokinetic properties include oral absorption, hepatic metabolism primarily via cytochrome P450 enzyme CYP3A4/5 with clinical interactions relevant to drugs from companies such as Pfizer and AstraZeneca, and a terminal half-life enabling once-daily dosing adopted in protocols at centers such as Johns Hopkins Hospital and Cleveland Clinic. Distribution to the central nervous system, demonstrated in imaging and clinical studies involving neuroradiology departments at Massachusetts General Hospital and Stanford Health Care, informs use for patients with brain metastases commonly managed at tertiary referral centers like UCLA Health.

Clinical trials and approval

Pivotal randomized and single-arm trials supporting osimertinib were conducted across academic networks including European Organisation for Research and Treatment of Cancer, Lung Cancer Group Netherlands, and cooperative groups affiliated with Alliance for Clinical Trials in Oncology, producing publications in journals such as The New England Journal of Medicine, The Lancet Oncology, and Journal of Clinical Oncology. Key studies compared osimertinib with first-generation EGFR inhibitors marketed by AstraZeneca and Eli Lilly and generated data leading to accelerated and full approvals by the Food and Drug Administration and conditional approvals by the European Medicines Agency, with label expansions following outcome reporting to health agencies in Japan, Australia, and Canada. Industry sponsorship and collaborations involved the manufacturer and global clinical research organizations working with institutions like National Cancer Institute and academic trial sites including Princess Margaret Cancer Centre.

Adverse effects and safety

Common toxicities observed in trials and postmarketing surveillance include dermatologic events, diarrhea, and laboratory abnormalities evaluated in safety oversight committees at multicenter consortia such as those organized by International Conference on Harmonisation guidelines, and serious events like interstitial lung disease/pneumonitis and cardiotoxicity necessitating monitoring by cardiology services at centers such as Mount Sinai Health System and pulmonary medicine teams at Toronto General Hospital. Risk management plans and boxed warnings implemented by regulators reference pharmacovigilance frameworks used by World Health Organization, European Medicines Agency, and national pharmacovigilance centers to collect adverse event reports submitted by hospitals like Beth Israel Deaconess Medical Center and cancer registries maintained by organizations such as SEER Program. Drug–drug interactions, particularly with strong CYP3A inducers or inhibitors marketed by firms such as Gilead Sciences and Novartis, can alter exposure and require coordination with clinical pharmacists at institutions including Fred Hutchinson Cancer Center.

Dosing and administration

Standard dosing is once daily oral administration in tablet form, with dosing strategies and modifications described in prescribing information and clinical practice guidelines from bodies like National Comprehensive Cancer Network, European Society for Medical Oncology, and specialty societies including International Association for the Study of Lung Cancer. Dose adjustments for toxicity, hepatic impairment, and concomitant CYP3A modulators are guided by pharmacology data and institutional protocols used at hospitals such as Brigham and Women's Hospital and Vanderbilt University Medical Center. Administration considerations for combinations with chemotherapy regimens used at centers like MD Anderson Cancer Center follow trial-defined schedules and safety monitoring frameworks endorsed by regulatory agencies.

Mechanism of resistance

Acquired resistance mechanisms documented through genomic analyses by laboratories at Broad Institute and sequencing consortia reveal on-target secondary EGFR alterations, bypass track activation involving oncogenes such as MET amplification, and histologic transformation events similar to patterns observed in studies of small cell transformation reported by groups at Dana-Farber Cancer Institute and Vanderbilt-Ingram Cancer Center. Research into combination therapies and next-generation agents involves collaborations between academic centers, biotechnology companies, and consortia like Stand Up To Cancer and public–private partnerships with funders such as National Institutes of Health to address emergent resistance pathways characterized by liquid biopsy platforms from vendors like Guardant Health and tissue-based assays from academic pathology laboratories.

Category:Antineoplastic drugs